Anlon Healthcare Q2 PAT jumps over 3.6x YoY; IPO funds used on track

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹14.31

prior close

₹14.76

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+2.2% vs market

Pharmaceuticals peers, median of 157sector-0.2%+2.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.4

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-0.3+2.2-0.2+2.2

Next day

-1.6+0.7-2.3+0.5-2.1

+0.2+0.6-0.4+0.6-0.4

-0.8+0.5-1.3+0.5-1.3

+4.8+1.1+3.7+0.2+4.6

+10.1+0.3+9.9-0.6+10.8

+9.3-0.2+9.5-1.1+10.4

15d

+10.0-2.2+12.2-2.1+12.1

-1.3-4.9+3.6-3.2+1.9

-5.0-7.5+2.5-5.9+1.0

-14.0-4.8-9.3-6.4-7.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 revenue rose to Rs 52.20 crore from Rs 24.17 crore YoY, more than doubling. H1 FY26 PAT surged to Rs 12.86 crore from Rs 6.36 crore YoY. EPS stood at Rs 3.07 versus Rs 2.56. Company listed on Sept 3, 2025. Rs 121.03 crore raised via IPO, Rs 82.45 crore utilized with no deviation reported. Auditor RVD and Co gave a clean review.

Likely market impact

Strong revenue and profit growth; IPO proceeds being deployed as planned, a positive signal for new shareholders